FiercePharma

Bristol-Myers Squibb commercial chief Murdo Gordon jumps ship ahead of key Opdivo launch

Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and Chief Commercial ...
MM&M

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

Bristol-Myers Squibb plans to spend more money on direct-to-consumer advertising for its immuno-oncology drug, Opdivo, company executives told investors during a first-quarter earnings call. BMS CFO ...
FiercePharma

Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer

Bristol Myers Squibb snagged an FDA go-ahead to open another front in Opdivo's rivalry with Merck & Co.'s Keytruda. The FDA approved the combination of Opdivo and Exelixis’ tyrosine kinase inhibitor ...
Nasdaq

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of ...

If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...
MM&M

Infographic: Merck’s Keytruda versus Bristol-Myers Squibb’s Opdivo

Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more. In a world where healthcare is moving fast, HCG is moving faster. Always ahead of the ...